ArticleBlood neoplasia2026
Racial and socioeconomic differences in time to treatment initiation and outcomes in aggressive non-Hodgkin lymphoma.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Racial and socioeconomic differences in cancer treatment timing are recognized in solid tumors, but comparable data in aggressive non-Hodgkin lymphoma (NHL) remain limited. Using the National Cancer Database (2004-2022), we conducted a retrospective cohort study of 271 472 patients with diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, mantle cell lymphoma (MCL), and peripheral T-cell lymphoma (PTCL) who received multiagent chemotherapy. Time to treatment initiation (TTI) was defined as days from diagnosis to initiation of multiagent chemotherapy. Multivariable logistic regression identified factors associated with TTI ≥31 days, and Cox proportional hazards models assessed associations between TTI and overall survival. Median TTI was 23 days (interquartile range, 12-38). Black patients had higher odds of TTI ≥31 days than White patients across subtypes (adjusted odds ratio range, 1.20-1.34), and Hispanic patients had higher odds in selected subtypes. TTI lengthened over time, with patients diagnosed in 2016-2022 experiencing 18% to 31% higher odds of TTI ≥31 days than those diagnosed in 2004 to 2009. A shorter TTI was associated with worse survival across all subtypes (adjusted hazard ratio range, 0.65-0.85 for 31-60 days vs ≤30 days), likely reflecting confounding by indication. In primary models, Black race was independently associated with higher mortality; however, inverse probability of treatment weighting analyses attenuated Black-White survival differences in DLBCL, Burkitt lymphoma, and MCL, whereas excess mortality persisted in PTCL. These findings highlight racial differences in treatment timing across aggressive NHL subtypes and subtype-specific heterogeneity in survival outcomes, supporting system-level interventions to improve equitable lymphoma care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.